Abstract
Aim: To study the efficacy and safety of systemic methacycline in moderate inflammatory acne vulgaris. Patients and Methods: An open-label non comparative study was carried out for 8 weeks at the Department of Dermatology and Plastic Surgery of "La Sapienza" University in Rome. Twenty-five patients (11 women, 14 men), between 15 and 35 years of age (mean age ± 22 years), affected by moderate inflammatory acne vulgaris, were enrolled in this study. Patients were treated with topical adapalene 0,1% gel o cream (in the evening) in association with systemic methacycline (300 mg orally twice daily for 6 weeks of therapy, then 300 mg orally once daily for the last two weeks). Patients were examined at baseline, 4 weeks and 8 weeks (end of study), evaluating both clinical (Global Acne Grading System, GAGS) and quality of life (Acne Quality of Life Questionnaire, AQoL) improvement. Results: 22 patients completed the study and showed significant improvement. Side effects (abnominal pain) were recorded in only 4 patients and 3 of them interrupted the treatment. Conclusion: Systemic methacycline is a safe and effective treatment of moderate inflammatory acne vulgaris with an excellent patient compliance.
| Original language | Italian |
|---|---|
| Pages (from-to) | 15-18 |
| Number of pages | 4 |
| Journal | Dermatologia Clinica |
| Volume | 26 |
| Issue number | 1 |
| Publication status | Published - Jan 2006 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
Cite this
Efficacia della metaciclina nell'acne moderata : Risultati preliminari. / Innocenzi, D.; Rota, C.; Pacifico, V.; Bruni, F.; Lupi, F.; Panetta, C.; Skroza, N.
In: Dermatologia Clinica, Vol. 26, No. 1, 01.2006, p. 15-18.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacia della metaciclina nell'acne moderata
T2 - Risultati preliminari
AU - Innocenzi, D.
AU - Rota, C.
AU - Pacifico, V.
AU - Bruni, F.
AU - Lupi, F.
AU - Panetta, C.
AU - Skroza, N.
PY - 2006/1
Y1 - 2006/1
N2 - Aim: To study the efficacy and safety of systemic methacycline in moderate inflammatory acne vulgaris. Patients and Methods: An open-label non comparative study was carried out for 8 weeks at the Department of Dermatology and Plastic Surgery of "La Sapienza" University in Rome. Twenty-five patients (11 women, 14 men), between 15 and 35 years of age (mean age ± 22 years), affected by moderate inflammatory acne vulgaris, were enrolled in this study. Patients were treated with topical adapalene 0,1% gel o cream (in the evening) in association with systemic methacycline (300 mg orally twice daily for 6 weeks of therapy, then 300 mg orally once daily for the last two weeks). Patients were examined at baseline, 4 weeks and 8 weeks (end of study), evaluating both clinical (Global Acne Grading System, GAGS) and quality of life (Acne Quality of Life Questionnaire, AQoL) improvement. Results: 22 patients completed the study and showed significant improvement. Side effects (abnominal pain) were recorded in only 4 patients and 3 of them interrupted the treatment. Conclusion: Systemic methacycline is a safe and effective treatment of moderate inflammatory acne vulgaris with an excellent patient compliance.
AB - Aim: To study the efficacy and safety of systemic methacycline in moderate inflammatory acne vulgaris. Patients and Methods: An open-label non comparative study was carried out for 8 weeks at the Department of Dermatology and Plastic Surgery of "La Sapienza" University in Rome. Twenty-five patients (11 women, 14 men), between 15 and 35 years of age (mean age ± 22 years), affected by moderate inflammatory acne vulgaris, were enrolled in this study. Patients were treated with topical adapalene 0,1% gel o cream (in the evening) in association with systemic methacycline (300 mg orally twice daily for 6 weeks of therapy, then 300 mg orally once daily for the last two weeks). Patients were examined at baseline, 4 weeks and 8 weeks (end of study), evaluating both clinical (Global Acne Grading System, GAGS) and quality of life (Acne Quality of Life Questionnaire, AQoL) improvement. Results: 22 patients completed the study and showed significant improvement. Side effects (abnominal pain) were recorded in only 4 patients and 3 of them interrupted the treatment. Conclusion: Systemic methacycline is a safe and effective treatment of moderate inflammatory acne vulgaris with an excellent patient compliance.
KW - Inflammatory acne vulgaris
KW - Methacycline
UR - http://www.scopus.com/inward/record.url?scp=33745683726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745683726&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:33745683726
VL - 26
SP - 15
EP - 18
JO - Dermatologia Clinica
JF - Dermatologia Clinica
SN - 0392-1395
IS - 1
ER -